David H. Kirn
David H. Kirn (pronunciation: Day-vid H. Kern) is a prominent figure in the field of oncolytic virotherapy, a form of cancer treatment that uses viruses to selectively kill cancer cells.
Etymology
The name "David" is of Hebrew origin, meaning "beloved". The middle initial "H" and the surname "Kirn" do not have known etymologies.
Career
David H. Kirn is the co-founder and Chief Executive Officer of 4D Molecular Therapeutics, a company that focuses on the development of targeted and personalized gene therapy products. Prior to this, he was the founder and CEO of Jennerex Biotherapeutics, a company that specialized in the development of oncolytic viruses for cancer treatment.
Contributions to Oncolytic Virotherapy
Kirn's work in oncolytic virotherapy has led to significant advancements in the field. He has been involved in the development of several oncolytic viruses, including JX-594, a modified vaccinia virus that has shown promise in clinical trials for the treatment of liver cancer.
Related Terms
- Oncolytic Virotherapy
- Cancer Treatment
- 4D Molecular Therapeutics
- Jennerex Biotherapeutics
- JX-594
- Gene Therapy
External links
- Medical encyclopedia article on David H. Kirn
- Wikipedia's article - David H. Kirn
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski